Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Summary of recent changes (last updated May 20, 2022):
- New guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5–11 years
- Updated guidance that the following people should receive a second COVID-19 booster dose:
- People ages 12 years and older who are moderately or severely immunocompromised
- People ages 50 years and older
- Updated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-depleting therapies
- Clarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A)
- Updated guidance for primary series vaccination after SARS-CoV-2 infection
Get Email Updates
Receive email updates about this page.
COVID-19 Vaccines, Recommendations, and Schedule
Special Situations and Populations
Appendices
- People who received COVID-19 vaccine outside the United States (Appendix A)
- People who received COVID-19 vaccine as part of a clinical trial (Appendix B)
- Vaccine administration errors and deviations (Appendix C)
- Guidance for people who are moderately or severely immunocompromised and vaccinated with Janssen COVID-19 vaccine (Appendix D)
- Triage of people with a history of allergies or allergic reactions (Appendix E)
- Ingredients included in COVID-19 vaccines (Appendix F)
More about the Interim Clinical Considerations
See the FAQ page for answers to commonly asked questions about the Interim Clinical Considerations.
Page last reviewed: May 20, 2022
Content source: National Center for Immunization and Respiratory Diseases